Novo Nordisk tries to tackle Ablynx and bring it into the fold with a $3B buyout offer, but the biotech keeps saying no
Playing a hot hand with a promising late-stage asset and a newly completed $200 million IPO, Ablynx has waved away two bids by Novo Nordisk to acquire the company for a hefty premium with a bid of up to $3.1 billion.
But Novo isn’t taking no for an answer.
The Danish biopharma company says it’s going public with its offer in an attempt to put pressure on the biotech to start some serious negotiations. And Novo says it’s not just interested in caplacizumab, which is being developed for an ultra rare blood clotting disorder. The company wants to swallow Ablynx whole, taking over the entire pipeline and keeping the European operations Ablynx has built up in Belgium as it advanced its antibody technology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.